Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key therapeutic advances, standout presentations, emerging trends in oncology treatment, ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab ... Products for Human Use recommended the approval of the drug in combination with gemcitabine and cisplatin as ...

The drug also reduced the risk of death by 25% in that study, representing the first PD-1/L1 inhibitor to deliver a survival win for MIBC patients. Meanwhile, Pfizer recently tested its ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

Imfinzi works by targeting the PD-L1 protein, releasing the inhibition of immune responses and allowing the body to attack tumor cells. This drug is part of AstraZeneca’s broader effort to ...

On Thursday, the FDA approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...